Adult immunization recommendations in the US—New changes and a plea for a global adult immunization schedule

Vaccine ◽  
2012 ◽  
Vol 30 (24) ◽  
pp. 3489-3491 ◽  
Author(s):  
Gregory A. Poland ◽  
Diane Peterson ◽  
Pierce Gardner
2010 ◽  
Vol 13 (3) ◽  
pp. A190
Author(s):  
J Campbell ◽  
DC Taylor ◽  
ME Skornicki ◽  
VC Sood ◽  
B Arondekar ◽  
...  

2010 ◽  
Vol 43 (2) ◽  
pp. 5
Author(s):  
DIANA MAHONEY

2020 ◽  
Vol 27 (1) ◽  
pp. 123-133 ◽  
Author(s):  
Freddy Caldera ◽  
Dana Ley ◽  
Mary S Hayney ◽  
Francis A Farraye

Abstract Recent advances in the treatment of inflammatory bowel disease (IBD) include the use of immune modifiers and monoclonal antibodies, such as tumor necrosis factor (TNF) alpha inhibitors, anti-integrin agents, janus kinase inhibitors, and interleukin-12/23 inhibitors. These agents achieve higher rates of clinical remission and mucosal healing than conventional therapy. However, these therapies increase the risk of infections, including some vaccine-preventable diseases. Infections are one of the most common adverse event of immunosuppressive therapy. Thus, providers should optimize immunization strategies to reduce the risk of vaccine-preventable infections in patients with IBD. There are several newly licensed vaccines recommended for adults by the US Advisory Committee on Immunization Practices. This review will focus on how gastroenterology providers can implement the adult immunization schedule approved by ACIP for patients with IBD.


2019 ◽  
Vol 170 (3) ◽  
pp. 182 ◽  
Author(s):  
David K. Kim ◽  
Paul Hunter ◽  

2005 ◽  
Vol 29 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Matthew M. Davis ◽  
Lakshmi K. Halasyamani ◽  
Vishnu-Priya Sneller ◽  
Kathy R. Bishop ◽  
Sarah J. Clark

Sign in / Sign up

Export Citation Format

Share Document